
Amgen recently announced early phase 3 CANDOR study data, showing the triple-drug combination of carfilzomib (Kyprolis), along with dexamethasone and daratumumab (Darzalex, sold by Janssen), met its primary end point of progression-free survival in patients with relapsed or refractory multiple myeloma, with a 37% reduction in the risk of progression or death.

































